Matthew Shields
Known title: EVP, Global OperationsCIK: 0002025621
Associated companies
this person other insiders at TEVA
Transaction History
| TEVA | ▼ Sell | Open Market | 9,989 | $322K | 6/18/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 16,195 | — | 6/3/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 16,195 | $532K | 6/3/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 17,295 | — | 3/5/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 17,295 | $548K | 3/5/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 16,195 | — | 6/3/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 6,206 | $106K | 6/3/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.